SITC 2022 Late-Breaking Abstracts Announced

FOR IMMEDIATE RELEASE
Nov. 2, 2022



Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer's 37th Annual Meeting

MILWAUKEE – The Society for Immunotherapy of Cancer (SITC) received a record-breaking number of abstract submissions in 2022, more than 1,500, and has announced titles and authors for late-breaking abstracts (LBA). The abstracts will be presented at SITC’s upcoming 37th Annual Meeting & Pre-Conference Programs taking place November 8–12, 2022, in Boston, MA and virtually.

 “SITC is excited to incorporate these abstracts into an already impressive group of abstracts. The late-breaking abstracts will round out the content offered at the 37th Annual Meeting and highlight more cutting-edge research and data,” said SITC President Patrick Hwu, MD.

The late-breaking abstracts are:

  • (1468) First data readout of standardized transcriptional profiling for optimizing cellular therapies: A Multi-Center PICI-NanoString collaboration

         Sarah Church, PhD – NanoString Technologies

  • (1469) A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic disease

         Sandip Patel, MD – University of California San Diego Moores Cancer Center

  • (1470) Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)

         Wade T. Iams, MD – Vanderbilt University Medical Center

  • (1471) Pharmacodynamic and predictive biomarkers associated with response in cancer patients treated with TPST-1120: a first-in-class, small molecule antagonist of Peroxisome-Proliferator Activated Receptor-Alpha

         Nathan Standifer, PhD – Tempest Therapeutics

  • (1472) Assessing the Correlation between CD8 Cell PET Imaging with 89-Zr-Crefmirlimab Berdoxam and CD8 Cell Immunohistochemistry in Patients with Advanced Cancer Receiving Immunotherapy

         Michael Postow, MD – Memorial Sloan Kettering Cancer Center

  • (1473) Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial

         Celeste Lebbe, MD, PhD – Université Paris Cite, Dermatolo-Oncology AP-HP Hôpital Sain

  • (1474) Cancer Vaccine Plus PD-1 Blockade Promotes Infiltration of Melanoma Metastases by Vaccine-Induced T Lymphocytes
  •  Christine Tran, MD – University of Virginia
  • (1475) A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors

         Paul Baverel, PhD – Molecular Partners AG

  • (1477) First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma.

         Patrick Wen, MD – Dana Farber Cancer Institute

  • (1478) A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells

         Stefanie Mandl, PhD – PACT Pharma
         Antoni Ribas, MD, PhD - University of California Los Angeles

The full abstracts will be available on Nov. 7 at 8 a.m. EST as a supplement published in the Journal for ImmunoTherapy of Cancer (JITC).

Late-Breaking Abstract Sessions with oral abstract presentations will take place on Thursday, Nov. 10 from 11:10–11:40 a.m. EST and Friday, Nov. 11 from 11:25–11:55 a.m. EST. Late-Breaking Abstract posters will be presented in the Poster Hall in Boston, MA and the virtual ePoster Hall beginning Thursday, Nov. 10 at 9 a.m. EST.

To learn more about the late-breaking abstracts, visit the 37th Annual Meeting & Pre-Conference Programs website.


About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at www.sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

Media Contact

Thomas Martin, Communications and Membership Director
tmartin@sitcancer.org
(414) 271-2456